Showing results (981-990 of 1,996) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|February 16, 2024
Potential treatment targets for migraine: emerging options and future prospectsChia-Chun Chiang, Frank Porreca, Carrie E Robertson, et al.
The Lancet. Neurology|October 20, 2023
Global, regional, and national burden of spinal cord injury, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
The Lancet. Neurology|October 15, 2023
Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attackLuciano A Sposato, Thalia S Field, Renate B Schnabel, et al.
The Lancet. Neurology|October 15, 2023
Radiologically isolated syndromeChristine Lebrun-Frenay, Orhun Kantarci, Aksel Siva, et al.
The Lancet. Neurology|July 21, 2023
Differential diagnosis of suspected multiple sclerosis: an updated consensus approachAndrew J Solomon, Georgina Arrambide, Wallace J Brownlee, et al.
The Lancet. Neurology|July 21, 2023
Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort studyKimford J Meador, Morris J Cohen, David W Loring, et al.
The Lancet. Neurology|July 21, 2023
Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
The Lancet. Neurology|August 18, 2023
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trialMona Guterud, Helge Fagerheim Bugge, Jo Røislien, et al.
The Lancet. Neurology|June 23, 2023
Frequency of euthanasia, factors associated with end-of-life practices, and quality of end-of-life care in patients with amyotrophic lateral sclerosis in the Netherlands: a population-based cohort studyRemko M van Eenennaam, Willeke Kruithof, Anita Beelen, et al.
The Lancet. Neurology|June 23, 2023
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trialJohn R Corboy, Robert J Fox, Ilya Kister, et al.
Pageof 200